Search - tctmd.com

Displaying 1 - 14 of 14

Sort: Relevancy | Date

News Daily News

NOBLE at 5 Years: New Data Favor CABG for Left Main Disease

Todd Neale

December 23, 2019

News Conference News VIVA 2019

Nearly 1 Year Later, Endovascular Community Continues to Struggle With Paclitaxel

L.A. McKeown

November 08, 2019

News Daily News

Repeat Target-Lesion PCI: An Option for Public Reporting?

Michael O'Riordan

October 25, 2019

News Daily News TCT 2019

BLADE-PCI: Antirestenotic Drug Flops in Diabetics, but Inflammation Hypothesis Lives On

L.A. McKeown

October 02, 2019

News Conference News TCT 2019

‘Spooky’ Signal Still Haunts Paclitaxel DCBs in PAD, but Updated Analysis Reassures

L.A. McKeown

September 28, 2019

News Daily News

FDA Advisors Face ‘Forest of Dueling Numbers’ at Paclitaxel PAD Device Review: Day One

L.A. McKeown

June 19, 2019

News Industry News

Concept Medical Inc. Granted "Breakthrough Device Designation" From FDA for Its MagicTouch Sirolimus Coated Balloon

May 02, 2019

Time and Money: PCI Public Reporting Requirements Takes Their Toll

News Conference News ACC 2019

Time and Money: PCI Public Reporting Requirements Take Their Toll

Michael O'Riordan

March 26, 2019

News Conference News CRT 2019

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

L.A. McKeown

March 06, 2019

News Daily News

No Excess Mortality Risk With Paclitaxel Stents in PAD, Second Medicare Analysis Finds

L.A. McKeown

March 01, 2019

News Daily News

Medicare Analysis Offers More Reassurances in Hullabaloo Over Paclitaxel-Based PAD Devices

L.A. McKeown

February 13, 2019

Presentation ISET 2019

Drug-Coated Therapy for ISR: Review of Options and Data

Presenter: Brian DeRubertis

January 30, 2019

News Daily News

Aspiration Thrombectomy on the Decline as New Study Affirms No Benefit in STEMI

Michael O'Riordan

January 15, 2019

News Daily News

Tailoring Antiplatelet Therapy to Bleeding Risk Post-PCI Improves Outcomes and Cuts Costs, Model Suggests

L.A. McKeown

January 08, 2019

Advertisement

NOBLE at 5 Years: New Data Favor CABG for Left Main Disease

Nearly 1 Year Later, Endovascular Community Continues to Struggle With Paclitaxel

Repeat Target-Lesion PCI: An Option for Public Reporting?

BLADE-PCI: Antirestenotic Drug Flops in Diabetics, but Inflammation Hypothesis Lives On

‘Spooky’ Signal Still Haunts Paclitaxel DCBs in PAD, but Updated Analysis Reassures

FDA Advisors Face ‘Forest of Dueling Numbers’ at Paclitaxel PAD Device Review: Day One

Concept Medical Inc. Granted "Breakthrough Device Designation" From FDA for Its MagicTouch Sirolimus Coated Balloon

Time and Money: PCI Public Reporting Requirements Take Their Toll

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

No Excess Mortality Risk With Paclitaxel Stents in PAD, Second Medicare Analysis Finds

Medicare Analysis Offers More Reassurances in Hullabaloo Over Paclitaxel-Based PAD Devices

Drug-Coated Therapy for ISR: Review of Options and Data

Aspiration Thrombectomy on the Decline as New Study Affirms No Benefit in STEMI

Tailoring Antiplatelet Therapy to Bleeding Risk Post-PCI Improves Outcomes and Cuts Costs, Model Suggests

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content